Upstream Bio vs Vertex Pharmaceuticals: Fair Value & Quality
Both stocks run through our valuation models. Here is how Upstream Bio (UPB) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 11, 2026.
As of Aug 11, 2026, Fair Value Calculator sees Upstream Bio as the less overvalued of the two: Upstream Bio trades at $7.25 versus a fair value of $6.21 (-14%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).
Upstream Bio
UPB · USD · Health Care
-14%
upside to fair value
overvalued
Price$7.25
Fair Value$6.21
Quality34/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-44%
upside to fair value
overvalued
Price$496
Fair Value$279
Quality79/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Upstream BioVertex Pharmaceuticals
Valuation
—P/E (TTM)28.8×
—P/S (TTM)10.06×
1.01×P/B6.59×
—EV/EBITDA23.8×
—PEG1.72×
Profitability
0%Net margin36%
—Operating margin38%
-42%Return on equity24%
-28%Return on assets12%
Growth
83%Revenue growth (YoY)8%
33.0%Avg. growth/yr (3Y)10.6%
—Avg. growth/yr (5Y)14.2%
Balance & size
—Debt / equity0.03×
$344MMarket cap$123B
expensiveGrowth qualityhealthy
Even match: 3 to 3 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Upstream Bioof which business quality 34 · market factors 4Vertex Pharmaceuticalsof which business quality 77 · market factors 65
ProfitabilityMargins and returns on capital today
0
72
Quality GrowthAre margins and returns improving?
37
65
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
40
58
Low VolatilityCalm price path (market factor)
0
86
MomentumPrice trend over the last 3–12 months (market factor)
9
54
52W MomentumDistance to the 52-week high (market factor)
3
59
Net IssuanceBuybacks instead of dilution
16
82
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Upstream Bio
Asset-Based$4.18
1 of 1 models see the stock below the current price.
Vertex Pharmaceuticals
DCF Models$453
Earnings-Based$516
Dividend Discount$7.07
Multiples$278
Asset-Based$49.27
Growth DCF$348
Economic Profit$254
Growth Earnings$692
18 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Upstream Bio
Bear $4.10Fair Value $6.21Bull $7.76
$7.25 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$496 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Upstream Bio · Health Care
Quality score34 · bottom 25%
Fair value upside-14% · above median
Vertex Pharmaceuticals · Health Care
Quality score79 · Top 25%
Fair value upside-44% · below median
Bottom line
As of Aug 11, 2026, Fair Value Calculator sees Upstream Bio as the less overvalued of the two: Upstream Bio trades at $7.25 versus a fair value of $6.21 (-14%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).
Vertex Pharmaceuticals has the higher quality score (79/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
